春立医疗(688236) - 2024 Q3 - 季度财报

Financial Performance - Revenue for Q3 2024 decreased by 49.03% year-on-year to ¥128,153,090.70, and year-to-date revenue decreased by 35.84% to ¥508,283,661.62[2] - Net profit attributable to shareholders for Q3 2024 was a loss of ¥17,874,633.27, with a year-to-date net profit of ¥61,151,445.55, down 66.14%[2] - The company reported a basic and diluted earnings per share of -¥0.05 for Q3 2024, a decrease of 65.96% year-to-date[2] - Total operating revenue for the first three quarters of 2024 was CNY 508.28 million, a decrease of 35.8% compared to CNY 792.16 million in the same period of 2023[17] - Net profit for the third quarter of 2024 was CNY 61.01 million, a decline of 66.2% compared to CNY 180.48 million in the same quarter of 2023[18] - Basic earnings per share for the third quarter of 2024 were CNY 0.16, down from CNY 0.47 in the same quarter of 2023[20] Assets and Liabilities - Total assets at the end of Q3 2024 were ¥3,494,818,114.71, a decrease of 4.24% from the end of the previous year[3] - Total assets as of the end of the third quarter of 2024 were CNY 3.49 billion, a decrease from CNY 3.65 billion at the end of 2023[16] - Total liabilities at the end of the third quarter of 2024 were CNY 698.38 million, down from CNY 770.33 million at the end of 2023[16] - Shareholder equity attributable to shareholders was ¥2,794,809,881.50, down 2.87% from the previous year[3] Cash Flow - The company's cash and cash equivalents amount to approximately ¥1.16 billion, a decrease from ¥1.27 billion in the previous period[14] - The cash inflow from operating activities was CNY 704,325,961.65, a decrease from CNY 897,101,117.43 in the same period of 2023, representing a decline of approximately 21.5%[21] - The net cash flow from operating activities was negative at CNY -17,279,413.75, compared to a positive CNY 13,749,157.98 in the first three quarters of 2023[21] - The ending balance of cash and cash equivalents was CNY 1,155,205,573.66, up from CNY 769,302,304.79 at the end of the same period in 2023[22] Research and Development - R&D investment in Q3 2024 was ¥32,016,993.64, accounting for 24.98% of revenue, an increase of 9.00 percentage points compared to the same period last year[3] - Research and development expenses for the first three quarters of 2024 were CNY 99.68 million, compared to CNY 114.74 million in the same period of 2023[18] Shareholder Information - Major shareholders include Shi Chunbao with 29.92% and Yue Shujun with 24.88% of shares[9] - The total number of ordinary shareholders is 7,998, with HKSCC NOMINEES LIMITED holding 95,125,425 shares, representing 24.5% of the total shares[12] - The total number of shares held by the top ten shareholders includes significant stakes from various investment funds, with the largest being HKSCC NOMINEES LIMITED[12] - There are no significant changes in the shareholding structure of the top ten shareholders compared to the previous period[13] Operational Challenges - The company experienced a significant decline in revenue due to the implementation of national volume-based procurement policies affecting product pricing[8] - The company reported a significant increase in contract liabilities, rising to CNY 227.59 million from CNY 149.56 million year-over-year[16] Other Financial Metrics - The weighted average return on equity decreased by 4.38 percentage points to -0.57%[3] - Non-recurring gains included government subsidies of ¥384,216.67 and fair value changes of financial assets totaling ¥4,447,357.07[5] - The company has not disclosed any related party transactions among the top ten shareholders[13] - The company did not apply new accounting standards or interpretations for the first time in 2024[23]